Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects - Wikidata - wikimedia - TriplyDB

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

http://www.wikidata.org/entity/Q34285711

about

Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy Apixaban and oral implications Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review Reversal of target-specific oral anticoagulants Atrial fibrillation management in older heart failure patients: a complex clinical problem Implications of apixaban for dental treatments Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis.Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Application of Molecular Modeling to Development of New Factor Xa Inhibitors Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease.Coagulation assessment with the new generation of oral anticoagulants.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin Apixaban.Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects.Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.The management of venous thromboembolism: A practical tool for the front-line clinician.Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.

P2860

Q24185813-27261825-12B8-45A6-A5E9-DADE6647FF63 Q26764874-6834A74A-5324-4E4F-AEB5-9E3643791ABD Q26766303-A94D2787-3454-44FD-BC81-16CAED7B3568 Q26780328-3E6EFD30-EE58-4D78-BB3B-62466A5CB24C Q26783455-E357A7D6-3D1D-4A7C-BD59-B9EA3EB06366 Q27003866-ED264C91-E557-4AE3-8A47-170C8F452E98 Q28076170-56C5D11C-45F0-4DB3-84EC-61743FBE1BE4 Q28079697-A9754954-E596-4A98-BEF3-0CF9529829FB Q28257188-F5E48335-0C2A-4B86-BB58-39056DB909F5 Q33694804-7190FA76-94C8-4B91-9190-496EB426BA43 Q33891915-17F537C9-CC9F-4179-BE81-06F3295F2739 Q34207558-071C67E5-7E3D-41CF-82EF-5FEC2A0B6B60 Q34413003-1FDA25FF-B02A-4FF3-92D6-B8B2F8820562 Q34482427-EF037D51-A329-431D-9A12-B2EE6E472CCF Q34531991-B4342711-6F22-4154-938D-7A65A802B780 Q34554473-7C54914D-5A5F-4A54-A0B0-A936E01F0D1D Q34666269-ACE7B700-7BA4-4BA7-9EA0-92A585344B82 Q34993935-8D449948-2182-472F-8E0E-34C80E5D96C5 Q35557449-95D9D70E-438C-4B3D-9962-CF1C0EB018EF Q35666219-117180F0-7477-46A9-BABC-29E790518D66 Q36100271-9DA483F0-A016-4F26-840C-20A0030FFDDD Q36119724-E3CEFF27-D4A8-4F4B-9D77-C940B89B0110 Q36331126-B6AD090F-D407-4C27-8680-6F759599295B Q36797336-53CCB175-32EA-4286-9271-4D44B4AE85F4 Q36836396-1BB94B99-405D-4934-9BB9-CDD89C42D35F Q36933789-3EBA2FF5-0E7D-4DBE-B5ED-EA7C1798FDC8 Q36968781-DE932397-D7E7-44BB-BF33-05333B4FC3CB Q37297475-FD0CE13E-4963-40D8-99FE-4DD9C9B5024E Q37312021-D0FE5DD5-5E2E-4229-83E1-C96C4E0E884D Q37340067-37EB8267-8AA1-4E18-A70F-C63960336C11 Q37353441-17D2D924-2D3D-48C6-8B66-39E5D7ECC06F Q37369329-4A8D0F48-5739-42B7-BCC7-D0705A380304 Q37388373-F9C4F0D4-A7A5-48B9-9F2C-71E683FAB93E Q37639007-9F072D04-A4B6-407F-AB69-1ABF0BDEA93B Q37653181-C3E076A6-07C6-4C9D-A660-7174293EEABA Q37741798-1F9CEE96-D423-412F-8010-614BF6B5F4E6 Q38107180-A8A9B4F4-ACF3-4ED3-89B2-56B0A8C8AC9D Q38116784-6713763E-1819-4B0E-9F1B-5F373BE6DEA7 Q38117418-BCDDE36C-C189-483A-9686-EEFAF4195DA5 Q38132255-A9BEE1D9-2488-491A-8203-7DDFE4BE1EE8

P2860

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

http://www.wikidata.org/entity/Q34285711

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@ast

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@en

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@nl

type

label

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@ast

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@en

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@nl

prefLabel

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@ast

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@en

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@nl

P1433

Q34285711-8E48571B-F4F5-4A4C-B226-8B53C193C997

P1476

Q34285711-ED288396-8182-4D32-8DD6-612E59018F23

P2093

Q34285711-081A4530-8516-492C-8E65-D9A1A3ECE982

Q34285711-0860C4CA-4A4C-4170-9200-30637806FAA5

Q34285711-23DF2E41-3E03-4F3F-874D-D507211A12C0

Q34285711-287236F4-D2D8-478A-BB05-45D6A6B6AE84

Q34285711-649EFEC5-6FD7-469C-AE4B-5054C0263BE0

Q34285711-69A574E4-8E77-4A39-8B1C-4C6F5BB5081C

Q34285711-C96A9859-135A-41CC-8FE6-80BE57A50F49

Q34285711-E8DF1AAA-7EA2-47FB-BC10-96D367E5A853

P2860

Q34285711-0966B797-DE4D-4975-A1A2-A90B28CC7F38

Q34285711-0D57F828-8827-4F01-B4F1-E9FE536DB81E

Q34285711-16E9A9ED-D30C-47A6-826A-36401AE8E9B6

Q34285711-172666CB-A34A-4C4E-8216-7BAD792C8039

Q34285711-1EF0A40E-2AEE-44AF-A0CE-E863AB0C2006

Q34285711-1F56A4DA-76BC-49B0-825B-FE9D4C3B0D36

Q34285711-21ABF828-68C6-470B-8630-62F37512DE09

Q34285711-28902A1A-61AB-4EDD-8B9A-5546F6A5BFBB

Q34285711-4882DFD5-5203-4BA8-B141-7818B3947D9B

Q34285711-4ECFD771-477F-44E1-89F7-DFB9CDC03086

P304

Q34285711-3E6D27C9-2DD2-4C9C-B962-FBA897061B52

P31

Q34285711-0794E5CA-348E-4A55-B32A-BAEF2E78CF76

P356

Q34285711-CD3F8BEE-AA20-4DBB-9390-5AD35ABD2A9B

P407

Q34285711-AAA0E05E-966A-4C97-8409-D0978A3B7B0B

P433

Q34285711-7130BC31-18CC-42DE-AC47-8AED89858F77

P478

Q34285711-4AE61CFD-83FF-461C-8CD5-3DE753182800

P577

Q34285711-749BF09E-739A-4D3D-883F-58C2F7986D05

P5875

Q34285711-02A0770A-A87C-4D09-90A1-0574556755A5

P698

Q34285711-835B1C28-BF27-432E-A812-EC7F7A782C1D

P921

Q34285711-3EEBA736-9F40-4690-ADA6-19BC49644648

P932

Q34285711-57B5F7F3-6DBC-4982-9623-CAFCA56CA847

P356

J.1365-2125.2012.04369.X

P1433

British Journal of Clinical Pharmacology

P1476

Apixaban, an oral, direct fact ...... ood effect in healthy subjects

@en

P2093

Alan Schuster

http://www.w3.org/2001/XMLSchema#string

Charles Frost

http://www.w3.org/2001/XMLSchema#string

Frank LaCreta

http://www.w3.org/2001/XMLSchema#string

Jessie Wang

http://www.w3.org/2001/XMLSchema#string

Richard A Reeves

http://www.w3.org/2001/XMLSchema#string

Rogelio Mosqueda-Garcia

http://www.w3.org/2001/XMLSchema#string

Sunil Nepal

http://www.w3.org/2001/XMLSchema#string

Yu Chen Barrett

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

Apixaban versus warfarin in patients with atrial fibrillation

Limitations of traditional anticoagulants.

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Strategies and progress towards the ideal orally active thrombin inhibitor.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

P304

476-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2012.04369.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228113818

http://www.w3.org/2001/XMLSchema#string

P698

22759198

http://www.w3.org/2001/XMLSchema#string

P921

P932

3558798

http://www.w3.org/2001/XMLSchema#string